학술논문
Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
22965262